Board of Directors

Helmy Eltoukhy, Ph.D. is the co-founder and chairman of the board of directors for Guardant Health and has served as the company’s Co-Chief Executive Officer since August 2021. Prior to founding Guardant, Dr. Eltoukhy held various positions at Illumina, Inc., or Illumina, from August 2008 to December 2012, including Senior Director of Advanced Technology Research, where he developed novel chemistries, hardware and informatics for genetic analysis systems. In June 2007, he co-founded Avantome Inc. to commercialize semiconductor sequencing to help speed up the democratization of high throughput DNA sequencing and served as Chief Executive Officer until its acquisition by Illumina in August 2008. He joined the Stanford Genome Technology Center, or SGTC, as a post-doctoral fellow in 2006 to work on low-cost DNA sequencing technologies. During his doctoral studies and at the SGTC, he developed the first semiconductor sequencing platform and first base-calling algorithm for next-generation sequencing under several National Human Genome Research Institute grants. He received his Ph.D., M.S. and B.S. degrees in electrical engineering from Stanford University.

AmirAli Talasaz, Ph.D. is the co-founder of Guardant Health and has served as the Co-Chief Executive Officer since August 2021. Prior to founding Guardant, Dr. Talasaz held various positions at Illumina, including Senior Director of Diagnostics Research from October 2011 to June 2012, where he led the efforts for emerging clinical applications of next-generation genomic analysis. During that time, he developed different genomic technologies suitable for clinical applications. In March 2008, he founded Auriphex Biosciences, Inc., which focused on purification and genetic analysis of circulating tumor cells for cancer management. The technology was acquired by lllumina in 2009. During his academic years, he led the Technology Development group at SGTC. He received his Ph.D. degree in electrical engineering, M.S. degree in electrical engineering and M.S. degree in management science and engineering from Stanford University.

Ian Clark has served as a member of the board of directors for Guardant Health since December 2016. Mr. Clark currently serves as Guardant’s Lead Independent Director and serves on the boards of directors of Corvus Pharmaceuticals, Inc., Shire Pharmaceuticals, Inc. and other privately-held companies, including Forty Seven, Inc. He is also a member of Forty Seven, Inc.’s audit committee, and he served on the board of directors and audit committee of Kite Pharma, Inc. from January 2017 to October 2017. He served as Chief Executive Officer of Genentech Inc., or Genentech, from January 2010 to December 2016. Prior to that, he was the Executive Vice President and Chief Marketing Officer of the Roche Group, or Roche, from April 2009 to December 2009. Prior to his time at Roche, Mr. Clark held several senior management positions at Genentech from January 2003 to March 2009, including Head of Global Product Strategy, Chief Marketing Officer, Senior Vice President, General Manager of BioOncology and Executive Vice President, Commercial Operations. Before joining Genentech, Mr. Clark spent 23 years in the biopharmaceutical industry in senior roles at Novartis International AG, Ivax Pharmaceuticals, Inc. and Sanofi S.A. in the United Kingdom, France and Eastern Europe. He started his career at G.D. Searle, LLC, a subsidiary of Monsanto Corporation, holding positions in sales and marketing. Mr. Clark received a B.S. degree in biology from South Hampton University.

• Chair of the Nominating and Corporate Governance Committee

Vijaya Gadde has served as a member of Guardant Health’s board of directors since June 2020. Ms. Gadde has served as Twitter, Inc.’s chief legal officer leading its legal, public policy, and trust and safety teams globally since 2011. Prior to joining Twitter in 2011, Ms. Gadde was senior director, legal at Juniper Networks; previously, for nearly a decade she worked at Wilson Sonsini Goodrich & Rosati. Ms. Gadde serves on the Board of Trustees of NYU Law School and the Board of Directors of Mercy Corps, a global humanitarian aid and development organization, which partners with communities, corporations, and governments. Ms. Gadde is also a co-founder of #Angels, an investment collective focused on funding diverse and ambitious founders pursuing bold ideas. Ms. Gadde earned a J.D. from New York University School of Law and a B.S. in industrial and labor relations from Cornell University.

• Chair of the Compensation Committee

Meghan Joyce has served as a member of Guardant Health’s board of directors since August 2021. Ms. Joyce currently serves as an independent advisor to select high growth organizations in the healthcare and consumer space. Previously, from September 2019 to April 2022, Ms. Joyce served as Chief Operating Officer and Executive Vice President of Platform at Oscar Health, a high-growth health tech and health insurance company, where she led operations, technology, clinical, marketing, and new business lines. Prior to joining Oscar Health, from 2013 to 2019, Ms. Joyce has held several leadership roles at Uber Technologies, most recently as Regional General Manager of the United States and Canada. Ms. Joyce has previously served as a Senior Policy Advisor at the United States Department of the Treasury, an investor at Bain Capital, and a consultant at Bain & Company. Ms. Joyce serves on the board of the Boston Beer Company (SAM). She holds an M.B.A degree from Harvard Business School and an B.A. degree in History from Harvard College.

• Member of the Audit Committee
• Member of the Nominating and Corporate Governance Committee

Steve Krognes has served as a member of Guardant Health’s board of directors since June 2022. Mr. Krognes is a professional independent board member in the biotech and life science sector. He currently serves as a director at Denali Therapeutics Inc., Gritstone bio, Inc. and RLS Global AB, and previously served on the board at Corvus Pharmaceuticals, Inc. between January 2016 and March 2021. Before becoming a board member of Denali Therapeutics, Mr. Krognes was the chief financial officer of the company from October 2015 to April 2022. In this role, he led the company’s IPO efforts and built the corporate finance, information technology and site organizations to enable the company to reach greater scale. Prior to Denali, he served in a variety of roles at large multinational corporations, including chief financial officer at Genentech, Inc. from April 2009 to September 2015 where he led the integration of Genentech and Roche Holding AG in the U.S. and the integration of Genentech and InterMune, Inc. He chaired the Genentech Access to Care Foundation between 2009 and 2015 and represented Genentech on the board and executive committee of the California Life Science Association. Prior to Genentech, Mr. Krognes was global head of mergers and acquisitions at Roche from January 2004 to April 2009. He also worked as an investment banker at Goldman Sachs, as a management consultant at McKinsey & Company and as a venture capitalist in Scandinavia. Mr. Krognes holds a Master of Business Administration from Harvard Business School and a Bachelor of Science in Economics from the Wharton School of the University of Pennsylvania.

• Chair of the Audit Committee
• Member of the Nominating and Corporate Governance Committee

Samir Kaul has served as a member of Guardant Health’s board of directors since April 2014. Mr. Kaul has been a General Partner at Khosla Ventures, a venture capital firm focusing on technology investing, since February 2006 and currently serves on the boards of directors of several private companies. He also served as a member of the board of directors of Gevo, Inc. from March 2013 to May 2014 and Amyris, Inc. from May 2006 to May 2012. Previously, Mr. Kaul was a member of Flagship Pioneering Inc., a venture capital firm, from June 2002 to May 2006. Prior to that, Mr. Kaul worked at the Institute for Genomic Research. Mr. Kaul holds a B.S. degree in biology from the University of Michigan, an M.S. degree in biochemistry from the University of Maryland and an M.B.A. degree from Harvard Business School.

• Member of the Compensation Committee

Myrtle Potter has served as a member of Guardant Health’s board of directors since October 2021. Ms. Potter has served as the Chief Executive Officer of Sumitovant Biopharma, Inc., the parent company of five biotechnology subsidiaries, since December 2019. Prior to this, she served as Vant Operating Chair at Roivant Sciences, Inc. from July 2018 to December 2019. In that role, she oversaw nine biopharmaceutical companies with over thirty investigational drugs in eleven therapeutic areas. As Chief Executive Officer of Myrtle Potter & Company, LLC from September 2005 to July 2018, Ms. Potter and her hand-picked team of experts led major strategic efforts and the preparation for multiple product launches for numerous biopharmaceutical companies. From 2000 to 2004, Ms. Potter served as Chief Operating Officer at Genentech, Inc., a biopharmaceutical company, and from 2004 to 2005, she served as the President, Commercial Operations and Executive Vice President of Genentech. Prior to joining Genentech, she held various positions, including President, U.S. Cardiovascular/Metabolics at Bristol-Myers Squibb, and Vice President at Merck & Co. While at Merck, she started the company Astra Merck Incorporated which later, through a series of transactions, became a part of AstraZeneca PLC. Ms. Potter currently serves on the board of Liberty Mutual Insurance Group, Opentrons Labworks, Inc. and the Board of Trustees of The University of Chicago, and has previously served on the boards of Amazon.com, Inc., Axsome Therapeutics, Inc., Express Scripts Holding Company, and Medco Health Solutions, Inc. Ms. Potter holds a Bachelor of Arts Degree from The University of Chicago.

• Member of the Audit Committee
• Member of the Compensation Committee

Musa Tariq has served as a member of Guardant Health’s board of directors since March 2023. Mr. Tariq currently serves as chief marketing officer of GoFundMe. He joined GoFundMe in January 2021 to further build the GoFundMe brand and drive the company’s marketing and communications functions. Prior to GoFundMe, Mr. Tariq was global head of marketing for Airbnb Experiences from September 2018 to December 2020 where he drove brand awareness and adoption of that rapidly growing part of Airbnb’s business. Before Airbnb, he was chief brand officer at Ford Motor Company from January 2017 to March 2018. Mr. Tariq has also held marketing leadership roles at Apple, Nike and Burberry and has a B.S. in Geography and Economics from London School of Economics. A distinguished counselor to iconic and emerging global brands, Mr. Tariq currently serves as an advisor to MasterClass, The British Fashion Council, Felix Capital and several other starts ups.

• Member of the Nominating and Corporate Governance Committee